Nuvalent, Inc.
NASDAQ:NUVLBiotechnology
-$0.03 today
- Market cap
- $9.13B
- Beta
- 1.15
- P/E (TTM)
- -21.6
- EPS (TTM)
- -$5.72
Volume 0.00M
Average 1.91M
NUVL Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Gross Margin history
Percent of revenue · from the income statement
No Gross Margin data reported for this period type.
Gross Margin vs competitors
How NUVL compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 99.6% | -0.4 pp | +4.8 pp | |
| LTM Jun 2026 | 93.2% | +1.8 pp | +3.0 pp | |
| LTM Jun 2026 | 88.7% | -11.3 pp | +243.1 pp | |
| LTM Sep 2026 | 88.2% | -1.2 pp | -1.2 pp | |
| LTM Sep 2026 | 64.2% | -21.2 pp | +3.0 pp | |
| LTM Sep 2026 | -558.9% | -202.1 pp | +18649.7 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding NUVL) | 88.5% | -6.2 pp | +3.9 pp | |
Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 35.56M | 63.73M | 113.24M | 217.77M | 306.97M |
| Selling, General & Admin | 10.26M | 22.38M | 36.25M | 62.59M | 107.34M |
| Operating Expenses | 45.82M | 86.11M | 149.49M | 280.37M | 414.31M |
| Depreciation & Amortization | 215K | 0 | 0 | 280.37M | 414.31M |
| EBITDA | (46.12M) | (81.85M) | (126.22M) | 20.38M | (10.49M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (45.82M) | (86.11M) | (149.49M) | (280.37M) | (414.31M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 23.27M | 38.32M | 44.74M |
| Interest Expense | 0 | 0 | 23.27M | 0 | 0 |
| Other Income / Expenses | (521K) | 4.25M | 23.27M | 20.38M | (10.49M) |
| Income Before Tax | (46.34M) | (81.85M) | (126.22M) | (259.99M) | (424.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 764K | 585K |
| Net Income | (46.34M) | (81.85M) | (126.22M) | (260.76M) | (425.38M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.13) | (1.65) | (2.17) | (3.93) | (5.85) |
| EPS (Diluted) | (2.13) | (1.65) | (2.17) | (3.93) | (5.85) |
| Weighted Avg Shares | 21.78M | 49.67M | 58.22M | 66.41M | 72.69M |
| Weighted Avg Shares (Diluted) | 21.78M | 49.67M | 58.22M | 66.41M | 72.69M |
Nuvalent, Inc.
NASDAQ:NUVL
Intrinsic Alpha fair value
Locked
Current Price
$123.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.